Non-small Cell Lung Cancer
Conditions
Brief summary
Our study aimed to evaluate the correlation between test reagent specific gene test results and the efficacy of relevant targeted drugs in patients with non-small cell lung cancer, and to support the continued registration of test reagents.
Interventions
None listed
Sponsors
Hunan Province Tumor Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1)≥18，advanced non-small cell lung cancer confirmed by histopathology, and were previously or currently treated with gefitinib tablets (as the first-line treatment) or osimertinib (first-generation TKI resistance treatment) or crizotinib capsules monotherapy were evaluated for efficacy. * 2\) Able to provide FFPE samples with a storage life of 5 years: Large specimen 5 pieces in each case; 10 puncture specimens in each case
Exclusion criteria
* 1\) Pathological evaluation of the tissue sample has too few tumor cells (total number of tumor cells \>20%); * 2\) Combination therapy with chemotherapy/radiotherapy/other targeted drugs/immunotherapy drugs; * 3\) Maintenance treatment when the disease does not progress after other anti-tumor treatments.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Consistency | October 2022-December 2022 | he consistency of efficacy between specified kit and 22C3 |
| ORR | October 2022-December 2022 | Objective response rate |
| PFS | October 2022-December 2022 | Progression free survival time |
Countries
China
Outcome results
None listed